Cell-based assays for Parkinson's disease using differentiated human LUHMES cells (original) (raw)

References

  1. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21–3.
    CAS PubMed Google Scholar
  2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68: 384–6.
    Article CAS Google Scholar
  3. Fearnley JM, Lees AJ . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283–301.
    Article Google Scholar
  4. Lees AJ, Hardy J, Revesz T . Parkinson's disease. Lancet 2009; 373: 2055–66.
    Article CAS Google Scholar
  5. Fahn S . The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47: S29.
    Google Scholar
  6. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW . The evolution and origin of motor complications in Parkinson's disease. Neurology 2000; 55: S13–20.
  7. Alberio T, Lopiano L, Fasano M . Cellular models to investigate biochemical pathways in Parkinson's disease. FEBS J 2012; 279: 1146–55.
    Article CAS Google Scholar
  8. Phlman S, Mamaeva S, Meyerson G, Mattsson ME, Bjelfman C, Ortoft E, et al. Human neuroblastoma cells in culture: a model for neuronal cell differentiation and function. Acta Physiol Scand Suppl 1990; 592: 25–37.
    Google Scholar
  9. Grau CM, Greene LA . Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease. Methods Mol Biol 2012; 846: 201–11.
    Article CAS Google Scholar
  10. Schule B, Pera RA, Langston JW . Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Biophys Acta 2009; 1792: 1043–51.
    Article Google Scholar
  11. Son JH, Chun HS, Joh TH, Cho S, Conti B, Lee JW . Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J Neurosci 1999; 19: 10–20.
    Article CAS Google Scholar
  12. Schmidt F, Champy P, Seon-Meniel B, Franck X, Raisman-Vozari R, Figadere B . Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture. PLoS One 2009; 4: e6215.
    Article Google Scholar
  13. Lotharius J, Falsig J, van Beek J, Payne S, Dringen R, Brundin P, et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005; 25: 6329–42.
    Article CAS Google Scholar
  14. Scholz D, Pöltl D, Genewsky A, Weng M, Waldmann T, Schildknecht S, et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 2011; 119: 957–71.
    Article CAS Google Scholar
  15. Langston JW, Langston EB, Irwin I . MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. Acta Neurol Scand Suppl 1984; 100: 49–54.
    CAS PubMed Google Scholar
  16. Singer TP, Ramsay RR, McKeown K, Trevor A, Castagnoli NE Jr . Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP+), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology 1988; 49: 17–23.
    Article CAS Google Scholar
  17. Lotharius J, O'Malley KL . The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem 2000; 275: 38581–8.
    Article CAS Google Scholar
  18. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7.
    Article CAS Google Scholar
  19. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879–84.
    CAS PubMed PubMed Central Google Scholar
  20. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364: 1167–9.
    Article CAS Google Scholar
  21. Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, et al. Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004; 101: 14966–71.
    Article CAS Google Scholar
  22. Studer L . Culture of substantia nigra neurons. Curr Protoc Neurosci 2001; Chapter 3: Unit.
  23. Hongo H, Kihara T, Kume T, Izumi Y, Niidome T, Sugimoto H, et al. Glycogen synthase kinase-3beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Biochem Biophys Res Commun 2012; 426: 94–9.
    Article CAS Google Scholar
  24. Diaz-Corrales FJ, Asanuma M, Miyazaki I, Miyoshi K, Hattori N, Ogawa N . Dopamine induces supernumerary centrosomes and subsequent cell death through Cdk2 up-regulation in dopaminergic neuronal cells. Neurotox Res 2008; 14: 295–305.
    Article CAS Google Scholar
  25. Smith PD, O'Hare MJ, Park DS . CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med 2004; 10: 445–51.
    Article CAS Google Scholar
  26. Alvira D, Tajes M, Verdaguer E, de Arriba SG, Allgaier C, Matute C, et al. Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neurons. Neuroscience 2007; 146: 350–65.
    Article CAS Google Scholar
  27. Petit-Paitel A, Brau F, Cazareth J, Chabry J . Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One 2009; 4: e5491.
    Article Google Scholar
  28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M . Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.
    Article CAS Google Scholar
  29. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK . Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121–34.
    Article Google Scholar
  30. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011; 72: 57–71.
    Article CAS Google Scholar
  31. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A 2009; 106: 20051–6.
    Article CAS Google Scholar
  32. Schildknecht S, Karreman C, Pöltl D, Efrémova L, Kullmann C, Gutbier S, et al. Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 2013; 30: 427–444.
    Article Google Scholar

Download references